Merck KGaA Wins FDA Approval for Abbisko-Discovered CSF-1R Inhibitor in TGCT
- The FDA approved pimicotinib (Pimjetmi), an oral CSF-1R inhibitor discovered by Abbisko, for symptomatic tenosynovial giant cell tumor where surgery would cause functional limitation or severe morbidity.
- Approval rests on the Phase 3 MANEUVER trial and follows earlier clearances in China, Canada and Switzerland.
- Merck KGaA holds worldwide commercialization rights.
💡 Points Based on public reports
This is a China-originated asset reaching the US through a mid-cap European partner, which is a template other Chinese biotechs will study. In a small indication, differentiation will turn on liver safety: Turalio carries a boxed warning and a REMS, so a cleaner label would be the commercial lever. Pricing and prescriber habit against Ono's and Daiichi's products now decide uptake.
📰 Source · Fierce Pharma ↗ Merck KGaA lands FDA nod in rare tumor disorder, portending Ono, Daiichi showdown